U.S. Machinery Stock News

If you are wondering whether FTAI Aviation's current share price lines up with its fundamentals, you are not alone. Many investors are asking the same question right now. The stock last closed at US$292.10, with returns of 6.7% over 7 days, 67.7% over 30 days, 38.9% year to date and 224.2% over 1 year, with the 3 year and 5 year returns both very large. Recent coverage around FTAI Aviation has focused on how its business model fits into broader themes in the aviation and leasing industry, as...

Revolution Medicines (NasdaqGS:RVMD) has attracted reported takeover interest from Merck, drawing fresh attention to the company and its pipeline. The interest surfaces as Revolution Medicines insiders, including General Counsel Jeff Cislini, have recently sold shares. Investors are weighing potential M&A activity alongside insider transactions and a sharply higher share price. Revolution Medicines enters this phase with strong recent share price moves, with the stock at $117.63 and up...

In recent weeks, Progyny received a series of analyst upgrades after meetings with management highlighted strong demand for its fertility benefits platform, improved earnings visibility, and nearly complete client retention heading into 2026. Analysts also emphasized Progyny’s breadth of over 600 employer clients and the absence of any single customer contributing more than 5% of revenue, underlining the resilience of its business model. Next, we’ll examine how this combination of...

Institutional investor commentaries highlight shifting sentiment on Doximity (NYSE:DOCS) following its latest quarterly results and outlook. The stock has faced pressure after cautious company guidance and recent healthcare policy changes. Hedge fund ownership has modestly increased, pointing to continued institutional interest despite recent share price moves. Doximity continues to focus on physician engagement, telehealth, and workflow tools as it responds to a rapidly changing digital...

If you are wondering whether Pursuit Attractions and Hospitality is offering fair value at its recent price, this article walks through the numbers in a straightforward way so you can judge for yourself. The stock recently closed at US$35.25, with returns of 5.3% over the last 7 days, 2.9% over 30 days, 5.5% year to date, 22.8% over 3 years and a 9.1% decline over 1 year, which gives a mixed picture of recent and longer term performance. Outside of regular trading updates, investors have...

If you are wondering whether STAAR Surgical's share price reflects its true value today, it helps to step back and look at how the market has been treating the stock recently. Over the last week, the share price return was 8.7% lower. The 30 day, year to date and 1 year returns were 18.0%, 18.9% and 21.7% lower respectively, and the 3 year and 5 year returns were 73.4% and 81.3% lower. This gives important context before judging any potential upside or downside. Recent coverage around STAAR...

If you are asking whether NCR Atleos at US$37.63 is a bargain, fully priced, or something in between, this article is going to walk you through the key signals that matter for valuation. The stock has moved around recently, with a 5.8% decline over the last 7 days, a 3.5% decline over the last 30 days, and returns of 1.1% year to date and 15.7% over the last year. Recent coverage has focused on NCR Atleos as a stand alone ATM and financial technology infrastructure business following its...

Riverwater Partners Sustainable Value Strategy has initiated a new position in Adeia Inc. (NasdaqGS:ADEA). The position reflects fresh institutional interest in Adeia's intellectual property business across media and semiconductor markets. Adeia focuses on licensing intellectual property that underpins media content distribution and semiconductor design, areas that remain central to how video is delivered and how chips are structured and manufactured. As streaming, connected devices and...

Omnicell, ticker NasdaqGS:OMCL, has expanded its digital healthcare focus with new medication management solutions. The company has launched its XT Amplify program, aimed at supporting hospitals and health systems with medication management. These moves highlight Omnicell's efforts to align its portfolio with outcome focused digital healthcare trends. At a share price of $50.3, Omnicell is coming off a mixed return profile, with the stock up 8.4% over the past 30 days and 11.4% year to...

Arbe Robotics (ARBE) is attracting fresh attention after a sharp move in both its shares and options, with recent trading sessions showing concentrated call option activity and heavier volumes than the average month. See our latest analysis for Arbe Robotics. The latest options activity comes after a volatile stretch where the 7 day share price return of 49.12% and 30 day share price return of 65.05% contrast with a 1 year total shareholder return loss of 43.14%. This suggests short term...

UFC has signed a multi year exclusive media rights agreement with FPT Play to broadcast UFC events in Vietnam. The deal gives FPT Play exclusive rights to distribute UFC content to viewers across Vietnam. For TKO Group Holdings (NYSE:TKO), which owns UFC, this agreement adds another piece to its international media footprint. UFC already has a global fan base, and Vietnam is a market with growing interest in combat sports and digital streaming. Partnering with an exclusive local distributor...

If you are wondering whether McKesson at around US$820 a share is still reasonably priced or starting to look expensive, you are in the right place. The stock has eased back recently, with a 2.4% decline over the last week and a 0.8% decline over the last month, although the 1 year return sits at 39.2% and the 3 year return at 119.5%. Recent coverage has focused on McKesson as one of the large distributors at the heart of the U.S. healthcare supply chain. This keeps it in the spotlight...

If you are wondering whether Moody's current share price still makes sense after a strong multi year run, this article will walk through what that price might imply about the company. Moody's closed at US$524.04, with a 2.8% decline over the last 7 days, a 1.3% gain over 30 days, a 5.0% gain year to date, a 7.8% gain over 1 year, a 68.1% gain over 3 years and a 105.2% gain over 5 years. Recent moves in the stock sit against an ongoing demand backdrop for credit ratings and analytics, as...

If you are wondering whether Interparfums at around US$98.76 is attractively priced or asking too much for its brand power, you are in the right place. The stock has recently shown sharp moves, with returns of 9.8% over 7 days and 15.8% over 30 days. It also carries a 27.8% decline over 1 year and a 6.1% decline over 3 years, alongside a 77.3% gain over 5 years. These mixed returns come against a backdrop of ongoing attention on branded fragrance and beauty companies, where investors have...

If you are wondering whether Assurant at around US$233 per share still offers value, you are not alone. The stock’s current price invites a closer look at what you are actually paying for. The share price closed at US$233.39, with returns of a 0.3% decline over 7 days, a 3.5% decline over 30 days and a 1.8% decline year to date, while the 1 year and 3 year returns stand at 12.4% and 88.5% respectively, and the 5 year return is 87.9%. Recent price moves sit against a backdrop of ongoing...

In January 2026, Manas AI announced a multi-year agreement granting it extensive access to Schrödinger’s physics-based computational drug discovery platform and expert support, aimed at integrating this technology with its AI “world model” for identifying diverse molecular binders. A key angle for investors is that Schrödinger’s tools will be tightly embedded into Manas AI’s large-scale discovery workflows, potentially reinforcing Schrödinger’s position in AI-enabled molecular design...

Oruka Therapeutics, Inc. recently reported positive interim data from its first-in-human Phase 1 trial of ORKA-002, showing a long half-life, sustained IL-17 inhibition and a class-consistent safety profile in healthy volunteers, while outlining multiple ongoing and planned psoriasis and hidradenitis suppurativa studies across its ORKA-001 and ORKA-002 programs. A key insight for investors is the early clinical evidence suggesting ORKA-002 may enable twice-yearly maintenance dosing,...

In January 2026, Ormat Technologies announced a US$25 million equity investment in Sage Geosystems and a long-term geothermal power purchase agreement with Switch, alongside securing Indonesia’s Telaga Ranu Geothermal Working Area concession. Together, these moves expand Ormat’s access to next-generation geothermal technology, deepen its role in data center decarbonization, and extend its project pipeline in Indonesia’s energy transition program. We’ll now examine how Ormat’s collaboration...

Earlier this month, Qnity Electronics reaffirmed its full-year 2025 net sales guidance of about US$4.70 billion and announced that long-time finance executive Mike Goss will serve as Interim Chief Financial Officer following Matt Harbaugh’s health-related departure. The combination of steady guidance and a seasoned interim CFO, who brings nearly three decades of experience at DuPont and Ernst & Young, has sharpened investor focus on Qnity’s role as a newly independent supplier of...

Burford Capital (NYSE:BUR) has drawn fresh attention after launching a planned $450 million private offering of senior notes due 2034. The proceeds are earmarked to redeem 2026 bonds and for broader corporate uses. See our latest analysis for Burford Capital. The planned 2034 notes come after a period of mixed market signals, with a 30-day share price return of 8.33% and a year-to-date share price return of 11.43%. The 1-year total shareholder return is 29.46% lower, suggesting recent...

In recent days, Payoneer India Pvt Ltd, a subsidiary of Payoneer Global Inc., received in-principle authorization from the Reserve Bank of India to operate as a Payment Aggregator – Cross Border, enabling it to facilitate both inward and outward transactions for Indian importers and exporters. This regulatory milestone, alongside Payoneer’s ongoing platform expansion through acquisitions and its focus on end-to-end solutions for small and mid-sized businesses, reinforces its push to embed...

Caledonia Mining (CMCL) has packed a lot into its latest update, combining Q4 and full year 2025 production figures, fresh 2026 guidance, a COO departure, and new convertible bond financing. See our latest analysis for Caledonia Mining. Those production figures, new 2026 guidance, COO departure and fresh convertible notes have landed alongside a strong share price move. The 1 day share price return is 6.05%, the 7 day return is 15.36%, the 30 day return is 15.91% and the year to date return...

POET Technologies recently completed a registered direct follow-on equity offering of 20,689,656 common shares at US$7.25 each, raising about US$150.00 million to fund acquisitions, research and development, and expansion of its optical module and light source businesses. This capital raise follows POET’s Product Innovation Award in China for its Teralight 1.6T optical engines, highlighting management’s intent to scale its AI-focused photonics platform using fresh institutional...

BillionToOne (BLLN) is back on investors’ radar after recent trading, with the share price around US$87.57 and mixed short term returns, including a 3.3% decline over the past day and a modest gain over the month. See our latest analysis for BillionToOne. Despite the recent 3.3% one day share price decline and a slightly negative year to date share price return of 1.93%, BillionToOne’s 1.42% 30 day share price return suggests momentum has been cautious rather than strongly trending in either...